Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

Diabetes Obesity and Metabolism(2024)10.1111/dom.15943Source: DataRank Database

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes is a research paper published in Diabetes Obesity and Metabolism (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.87)OA: greenTopics (47)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Huilin Tang ORCID,Hui Shao ORCID,Ying Lü ORCID,Lizheng Shi ORCID,Vivian Fonseca ORCID

Live enrichment

PubMed:39256938 PMC:PMC12135020 OpenAlex:https://openalex.org/W4402463590

NIDDK NIH HHS

Grant: R01DK133465

FWCI

1.87

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

green

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12135020/pdf/nihms-2082137.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12135020/

journalhttps://doi.org/10.1111/dom.15943

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39256938

Fields of Study

Diabetes Treatment and ManagementParkinson's Disease Mechanisms and TreatmentsMetabolism, Diabetes, and CancerHumansSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Parkinson DiseaseFemaleMaleAgedRetrospective StudiesUnited StatesDipeptidyl-Peptidase IV InhibitorsMedicareAged, 80 and overRisk FactorsIncidence

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsAgedAged, 80 and overDiabetes Mellitus, Type 2FemaleMedicareHumansMaleParkinson DiseaseRetrospective StudiesRisk FactorsUnited StatesIncidenceDipeptidyl-Peptidase IV Inhibitors

Keywords

MedicineType 2 diabetesInternal medicinePropensity score matchingDiabetes mellitusProportional hazards modelDipeptidyl peptidase-4Lower riskDipeptidyl peptidase-4 inhibitorHazard ratioRetrospective cohort studyPharmacologyEndocrinologyConfidence intervalParkinson diseaseSodium‐glucose Cotransporter 2 Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being